Cardiff Oncology (CRDF) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$508,000.00

Revenue (quarter)

$104,000.00

Revenue growth (year over year)

−14.05%

Gross profit (trailing twelve months)

$508,000.00

Gross margin

100.00%

Net income (trailing twelve months)

−$40.1M

Net income (quarter)

−$9.2M

Net income growth (year over year)

+33.79%

Net margin

−7884.06%

Return on equity

−94.14%

EPS (trailing twelve months)

−$0.60

Book value per share

$0.39

P/E (trailing twelve months)

—

Price to book

2.96

Debt to assets

28.92%

Payout ratio

—

Dividend yield

—

Company profile

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

• Is Cardiff Oncology (CRDF) profitable?

  No. Cardiff Oncology reported a net loss of $40.1M over the trailing twelve months.

• How much revenue does Cardiff Oncology (CRDF) make?

  Cardiff Oncology generated $508,000.00 in revenue over the trailing twelve months, down 14.05% year over year.

• How do I buy stock in Cardiff Oncology (CRDF)?

  CRDF trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.